Generic medicine manufacturers

Cipla, Teva and Fresenius Kabi take the lead in this group in 2020. All three are implementing policies that will help ensure antibacterial and antifungal medicines are promoted responsibly. Against a backdrop of greater disclosure, the leaders in this group are reported as taking additional steps against AMR compared to 2018.

Overall performance - in %

70%
63%
55%
53%
53%
31%
14%
11%
6%
CiplaFresenius KabiTevaAbbottMylanAurobindoAlkemSun PharmaHainan Hailing
Performance in 2020 Room to improve

Research Area performance - in points

11
7
10
8
6
8
7
6
9
4
7
10
5
7
9
3
8
5
4
2
90 80 60 40 20 0
CiplaFresenius KabiTevaAbbottMylanAurobindoAlkemSun PharmaHainan Hailing
R&D Appropriate Access Responsible Manufacturing Stewardship

Although disclosure remains comparatively low from this group, it has improved since 2018. The exceptions are Alkem, Hainan Hailing and Sun Pharma. Despite being big producers, they remain unwilling to share data and enable an evaluation of their commitment to limiting AMR.

Cipla, Teva and Fresenius Kabi take the lead, and all stand out for policies that will help ensure their medicines are promoted responsibly. Across all areas evaluated, Mylan and Abbott follow in joint fourth place. Cipla performs strongly in all areas where it was evaluated. It has filed all 10 of its relevant products in countries where need is highest,* takes part in AMR surveillance,** and is one of three companies in 2020 to fully decouple its sales agents’ bonuses from sales volumes, a significant step in mitigating against overselling, particularly as Cipla reports a global antibacterials sales volume of 2-3 billion units.***

Teva is one of the few companies not to use sales agents for antibacterial and antifungal medicines. It reports several strategies to ensure a continuous supply of antibacterials, including its Teva Access Initiative, which aims for a sustainable medicine supply in more countries than it currently does. The third leader in this group, Fresenius Kabi, limits its use of sales-related bonuses for sales agents by selling mainly through tenders without volume-linked bonuses. It has also disclosed guidelines for intensive care units on the appropriate use of its intravenous antibacterials.

Mylan leads the generic medicine manufacturers when it comes to ensuring a continuous supply of medicines. It has a global supply network of over 40 sites, uses dual sourcing and maintains safety and strategic stocks. It also deploys pricing strategies that take socioeconomic conditions into account, reporting that it provided medicines to more than 165 countries in 2018. 

Together with Cipla, Abbott outperforms peers in responsible manufacturing. For its own manufacturing sites, Abbott reports a comprehensive environmental risk-management strategy, including ongoing risk assessments and discharge limits for the majority of antibacterials manufactured. Abbott also expects third-party suppliers to follow its supplier guidelines. Along with Cipla, Abbott leads the group in registration filings. Its most widely filed product in this analysis is the antibacterial medicine clarithromycin, used to treat pneumonia, among other infections, which it has filed in 60 high-need countries.

What next

The leaders in this group show that all generic medicine manufactures can take practical steps to mitigate against the risk of overselling anti-infectives. Decoupling sales bonuses from sales volumes is particularly important, as many of these companies report pursuing a low-price/high-volume business model. Plus, as major producers of antibacterials, they have a particular responsibility to strengthen their strategies for environmental risk-management in manufacturing, and to require their suppliers to comply with comparable standards. Generic medicine manufacturers also have the possibility to support smaller R&D-focused companies (termed small- and medium-sized enterprises in the Benchmark) to bring important new medicines to low- and middle-income countries, by becoming co-development and manufacturing partners.


How generic medicine manufacturers are compared
Generic medicine manufacturers are evaluated in two research areas: Responsible Manufacturing and Appropriate Access and Stewardship. Not all companies are eligible for each metric in these areas, as the AMR Benchmark only evaluates companies in metrics that are relevant to its portfolio and/or pipeline. 

As a result, companies have different maximum possible scores and room to improve. Read more about the analytical framework here.


*102 low- and middle-income countries where bacterial and fungal infectious diseases are endemic, and where populations are more likely to lack access to antibacterial and antifungal medicines.

** This group of companies are not scored or evaluated in this area. The Benchmark does report on their surveillance activities, where known. From this group, Abbott, Cipla and Mylan are reported has supporting or running AMR surveillance activities.

*** ‘Standard units’, a measure of volume defined by IQVIA to represent a dose of a particular formulation of treatment.


Company trends

Large R&D-based companies

GSK leads the group in 2020, followed closely by Pfizer and Johnson & Johnson. Shionogi has moved up, in front of Novartis and Otsuka. All companies in this group take diverse action to limit AMR. However, only a few continue to expand efforts to safeguard this critical area of modern medicine.

Learn more

Generic medicine manufacturers

Cipla, Teva and Fresenius Kabi take the lead in this group in 2020. All three are implementing policies that will help ensure antibacterial and antifungal medicines are promoted responsibly. Against a backdrop of greater disclosure, the leaders in this group are reported as taking additional steps against AMR compared to 2018.

Learn more

Pharmaceutical SMEs

Entasis leads in 2020, followed closely by Wockhardt. Three leaders stand out for targeting bacteria in the highest threat category defined by WHO and the CDC, and for supporting late-stage projects with plans to ensure better access and good stewardship soon after launch. Transparency in this group has improved since 2018.

Learn more

Learn more

View our detailed overview of each company’s performance

Back to top |